Logo image
Back
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
Journal article   Open access

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

Eliot Y. Zhu, Jesse D. Riordan, Marion Vanneste, Michael D. Henry, Christopher S. Stipp and Adam J. Dupuy
NPJ precision oncology, Vol.6(1), pp.74-74
10/21/2022
DOI: 10.1038/s41698-022-00310-7
PMCID: PMC9587254
PMID: 36271142
url
https://doi.org/10.1038/s41698-022-00310-7View
Published (Version of record) Open Access

Abstract

Rare gain-of-function mutations in RAC1 drive drug resistance to targeted BRAF inhibition in cutaneous melanoma. Here, we show that wildtype RAC1 is a critical driver of growth and drug resistance, but only in a subset of melanomas with elevated markers of de-differentiation. Similarly, SRC inhibition also selectively sensitized de-differentiated melanomas to BRAF inhibition. One possible mechanism may be the suppression of the de-differentiated state, as SRC and RAC1 maintained markers of de-differentiation in human melanoma cells. The functional differences between melanoma subtypes suggest that the clinical management of cutaneous melanoma can be enhanced by the knowledge of differentiation status. To simplify the task of classification, we developed a binary classification strategy based on a small set of ten genes. Using this gene set, we reliably determined the differentiation status previously defined by hundreds of genes. Overall, our study informs strategies that enhance the precision of BRAFi by discovering unique vulnerabilities of the de-differentiated cutaneous melanoma subtype and creating a practical method to resolve differentiation status.
 Melanoma Predictive markers

Details

Metrics

8 Record Views
10 Times Cited - Web of Science
Logo image